Compare Expeditors International of Wshngtn Inc (EXPD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expeditors International of Wshngtn Inc vs Tango Therapeutics Inc. — how do they compare? Expeditors International of Wshngtn Inc trades at $197.41 (market cap $25.53B), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 6.8× Tango Therapeutics Inc.'s market cap, and Expeditors International of Wshngtn Inc pays a 0.82% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expeditors International of Wshngtn Inc for 44 Days and Tango Therapeutics Inc. for 0 Days on average.
| EXPD | TNGX | |
|---|---|---|
Market Cap | $25.53B | $3.74B |
Volume | 1,068,336 | 3,438,781 |
Sector | Industrials | Health |
52-Week High | $196.38 | $32.90 |
52-Week Low | $117.35 | $7.50 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $25.06B | $2.76B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXPD trades at $195.13, up 0.89% with a bullish technical signal supported by moving averages. The company shows strong profitability with 7.63% net margin and 42.6% ROE, though revenue growth has been modest. Recent earnings beats and positive analyst coverage highlight operational efficiency, while institutional activity shows mixed positioning.
Outlook remains cautiously optimistic with upside to the $220 high target, but valuation multiples appear stretched. Key risks include freight market volatility and competitive pressures. The stock's current price above consensus target suggests limited near-term upside despite strong fundamentals.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
